Earnings Report /

IbnSina Pharma: Solid operational performance confirms a better outlook for 2022

  • Solid revenues driven by growth across all business lines

  • Gross margin almost flat on strong wholesale business line growth

  • Bottom line surpasses revenue growth on slightly expanding margins and economies of scales achieved

Mariam Wael
Al Ahly Pharos Securities Brokerage
15 November 2021